We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-Label Study of ARD-0403 in Testosterone Deficient Men (ARD-0403-010)

This study has been terminated.
(Company strategic decision)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00562731
First Posted: November 22, 2007
Last Update Posted: April 1, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Ardana Bioscience Ltd
November 21, 2007
November 22, 2007
April 1, 2008
October 2007
Not Provided
Efficacy [ Time Frame: Study Duration ]
Same as current
Complete list of historical versions of study NCT00562731 on ClinicalTrials.gov Archive Site
Safety and Tolerability [ Time Frame: Study Duration ]
Same as current
Not Provided
Not Provided
 
Open-Label Study of ARD-0403 in Testosterone Deficient Men
A Phase III, Open-Label Follow-on Study for Long-Term Safety and Efficacy of Testosterone Cream, in Testosterone Deficinet Men Completing Study ARD-0403-004
Male hypogonadism, a disorder associated with testosterone deficiency, is frequently seen in clinical practice and has significant effects on patient well-being. The purpose of this study is to investigate the efficacy and safety of ARD-0403 as a testosterone replacement therapy in testosterone deficient men.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hypogonadism
Drug: ARD-0403
Daily transdermal ARD-0403
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
150
June 2008
Not Provided

Inclusion Criteria:

  • Testosterone deficiency
  • Completed study ARD-0403-004

Exclusion Criteria:

  • Previous treatment with testosterone replacement therapy within 4 weeks
  • Moderate-severe benign prostatic hypertrophy or prostatic cancer
  • Haematocrit >50%
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00562731
ARD-0403-010
Not Provided
Not Provided
Not Provided
Not Provided
Ardana Bioscience Ltd
Not Provided
Principal Investigator: R Swerdloff University of California, Los Angeles
Ardana Bioscience Ltd
March 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP